NCT05815160 – A Phase 1, Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination with Carboplatin and Etoposide in Adult Participants with Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
June 20, 2024
The primary purpose of part 1 (dose escalation) of this study is to identify the recommended phase 2 dose (RP2D) and to characterize the safety and tolerability of Debio 0123 in combination with carboplatin and etoposide.
The primary purpose of part 2 (dose expansion) of this study is to characterize the safety and tolerability of Debio 0123 at the RP2D when administered in combination with carboplatin and etoposide.